AIHealthcare Analytics

Knowledge Wiki

Wiki › FDA Regulatory Pathways for AI Medical Devices in 2026 — TEMPO Pilot and Generative AI Framework

FDA Regulatory Pathways for AI Medical Devices in 2026 — TEMPO Pilot and Generative AI Framework

CONCEPT
Rev 3 Oct 28, 2026 02:00 UTC 3 sources

The FDA in 2026 operates under dual regulatory pathways for AI medical devices: the TEMPO (Total Product Life Cycle Advisory Pilot) program for generative AI systems and traditional premarket review routes for deterministic AI algorithms. TEMPO enables manufacturers to bring generative AI medical devices to market with pre-authorization data while committing to post-market evidence generation. TEMPO represents a fundamental shift from FDA's traditional "all evidence before authorization" model to a "evidence generation pathway" approach. Manufacturers submit evidence of generative AI system architecture, safety testing, and evidence generation plans, with FDA authorization contingent on post-market data collection demonstrating clinical benefit and safety. The dual pathway creates regulatory complexity: manufacturers must determine whether their AI system qualifies as generative (eligible for TEMPO pathway) or deterministic (traditional review). The FDA's 2026 guidance emphasizes competency-based assessment, where AI systems earning "autonomy" through demonstrated performance can operate with reduced human oversight. This framework parallels medical licensure concepts, where clinicians earn autonomy through demonstrated competency. The approach remains controversial among health systems concerned about insufficient pre-market validation before clinical deployment. ---

Sources: harvested
🔒

Subscribe to read full wiki analysis

Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.

View Plans & Subscribe

New users get a 7-day trial — no credit card required.

← Back to Wiki Index